US59564R5000 - ADR
US$10M Registered Direct Offering and PIPE to Strengthen Balance Sheet of Combined Company
Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma
It's time for another breakdown of the biggest pre-market stock movers as we get ready for the opening bell on Wednesday!
ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 10, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that investigators from Columbia University Irving Medical Center and New York-Presbyterian will present interim results from their ongoing Phase 1 study on Midatech's MTX110 in Diffuse Intrinsic Pontine Glioma ("DIPG") at The International Symposium on Pediatric Neuro-Oncology ("ISPNO 2022") that will take place on 12-15 June 2022 in Hamburg, Germany. The presentation is titled: "A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas."
ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 10, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces that Rolf Stahel, Chairman and non-executive director, intends to retire after the Company's Annual General Meeting on 20 June 2022 ("AGM"). It is expected that Dr. Stephen Parker will be appointed as non-executive Chairman of the Board, following the AGM.
Fast Track Designation Granted to MTX110 Development for the Treatment of Recurrent Glioblastoma
ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 24, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces that its Notice of Annual General Meeting ("AGM") was posted to shareholders yesterday, along with the Annual Report for the year ended 31 December 2021. The documents are also available in the "Investors" section of the Company's website at www.midatechpharma.com/financial-reports-accounts.